Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| PRLD | PRESS-RELEASE | bullish | 5/10 | Prelude Therapeutics reported Q2 2026 EPS of -$0.14, beating consensus of -$0.18 by 22.2%, and generated $5.7M in revenu | Aug 11, 2026 |
| GANX | PRESS-RELEASE | bullish | 6/10 | Gain Therapeutics reported Q2 2026 EPS of -$0.11, beating consensus of -$0.15 by 26.7%, with net loss narrowing to $4.7M | Aug 11, 2026 |
| TNGX | PRESS-RELEASE | bullish | 7/10 | Tango Therapeutics reported Q2 2026 net loss of $0.37 per share, slightly wider than the $0.35 loss in Q2 2025, with zer | Aug 11, 2026 |
| HBIO | 8-K | mixed | 6/10 | Harvard Bioscience reported Q2 2026 revenue of $22.7M, up 11% YoY, beating the $21.4M consensus estimate. However, GAAP | Aug 11, 2026 |
| AURA | 8-K | bearish | 6/10 | Aura Biosciences reported Q2 2026 results with a net loss of $45.6M, wider than the $27.0M loss in Q2 2025, driven by in | Aug 11, 2026 |
| ACIU | PRESS-RELEASE | bullish | 7/10 | AC Immune received FDA Fast Track designation and IND clearance for its wholly owned anti-alpha-synuclein active immunot | Aug 11, 2026 |
| STTK | 8-K | bullish | 7/10 | Shattuck Labs reported Q2 2026 net loss of $0.12 per share, in line with consensus estimates of $-0.12. The key positive | Aug 11, 2026 |
| STTK | PRESS-RELEASE | neutral | 5/10 | Shattuck Labs reported Q2 2026 net loss of $0.12 per share, in line with consensus of -$0.12, with no revenue. The key p | Aug 11, 2026 |
| LTGO | CLUSTER | bullish | 6/10 | Two major insiders at Latigo Biotherapeutics (LTGO), a director/10% owner and a 10% owner entity, collectively purchased | Aug 11, 2026 |
| BAK | 6-K | neutral | 2/10 | Braskem filed three routine monthly 6-K reports disclosing insider securities holdings as required by Brazilian CVM Inst | Aug 11, 2026 |
| VIVS | EFFECT | bearish | 7/10 | VivoSim Labs' S-1 registration statement (File No. 333-297892) for a best-efforts public offering of up to $4,000,000 in | Aug 11, 2026 |
| CRL | CLUSTER | neutral | 3/10 | Two senior CRL executives (EVP & Chief People Officer and CEVP, Disc & Safety Assessment) sold a combined ~$2.41M in ope | Aug 11, 2026 |
| UTHR | CLUSTER | neutral | 2/10 | CEO Martine Rothblatt and EVP Paul Mahon sold a combined $989K in open-market shares within two days of United Therapeut | Aug 11, 2026 |
| BLSM | 8-K | neutral | 4/10 | BlossomHill Therapeutics completed its IPO on August 10, 2026, selling 9,375,000 shares at $16.00 per share for gross pr | Aug 10, 2026 |
| NXTC | 425 | bearish | 7/10 | NextCure (NXTC) filed a 425 communication announcing an additional $500 million private placement for Avere Therapeutics | Aug 10, 2026 |
| LTGO | 8-K | neutral | 5/10 | Latigo Biotherapeutics completed its IPO on August 10, 2026, selling 19,200,000 shares at $18.00 per share for gross pro | Aug 10, 2026 |
| PPBT | 6-K | neutral | 4/10 | Purple Biotech filed an updated corporate presentation on Form 6-K, highlighting its CAPTN-3 tri-specific antibody platf | Aug 10, 2026 |
| ALMS | 8-K | bullish | 7/10 | Alumis reported positive long-term Phase 3 ONWARD3 extension data for envudeucitinib in plaque psoriasis, showing 54% of | Aug 10, 2026 |
| CRVO | 8-K | neutral | 4/10 | CervoMed reported Q2 2026 results with a net loss of $6.6M ($-0.64 EPS, a 3.2% miss vs consensus $-0.62), no grant reven | Aug 10, 2026 |
| SANA | 8-K | neutral | 5/10 | Sana Biotechnology reported Q2 2026 GAAP net loss of $63.6M ($0.22/share), a narrower loss vs $93.8M ($0.39/share) in Q2 | Aug 10, 2026 |
| ALMR | 8-K | bullish | 7/10 | Alamar Biosciences reported Q2 2026 revenue of $29.4M (+82% YoY), beating the $25.9M consensus, and EPS of -$0.22, beati | Aug 10, 2026 |
| IMDX | 8-K | neutral | 6/10 | IMDX reported Q2 2026 revenue of $239K (GAAP net loss -$0.31/share), essentially pre-revenue as it awaits FDA authorizat | Aug 10, 2026 |
| MGX | 8-K | bearish | 5/10 | Metagenomi reported Q2 2026 results with a net loss of -$0.73 per share, wider than the -$0.63 consensus estimate, and c | Aug 10, 2026 |
| HROW | 8-K | mixed | 6/10 | Harrow reported Q2 2026 revenue of $70.7M, an 11% YoY increase and a 60% sequential jump, driven by strong branded produ | Aug 10, 2026 |
| PROK | 8-K | neutral | 5/10 | ProKidney reported Q2 2026 results with no revenue or EPS surprises vs consensus, as the company remains a pre-commercia | Aug 10, 2026 |
| NKTX | 8-K | bearish | 6/10 | Nkarta reported Q2 2026 net loss of $0.54 per share, significantly missing the consensus estimate of -$0.36 per share. T | Aug 10, 2026 |
| MIRM | 144 | neutral | 3/10 | Christopher Peetz, an officer and director of Mirum Pharmaceuticals, filed a Form 144 notice of intent to sell 20,000 sh | Aug 10, 2026 |
| AGMB | 6-K | neutral | 2/10 | Agomab Therapeutics filed a 6-K convening a special and extraordinary general shareholders' meeting on September 11, 202 | Aug 10, 2026 |
| RCKT | 8-K | bullish | 7/10 | Rocket Pharmaceuticals reported Q2 2026 GAAP net income of $123.2M ($1.09 basic EPS), driven by a $178.2M gain from the | Aug 10, 2026 |
| PALI | 8-K | neutral | 5/10 | Palisade Bio reported Q2 2026 results in line with Street consensus (EPS -$0.05 vs -$0.05 est), with no revenue surprise | Aug 10, 2026 |